IL146144A0 - Method and means for producing high titer, safe, recombinant lentivirus vectors - Google Patents

Method and means for producing high titer, safe, recombinant lentivirus vectors

Info

Publication number
IL146144A0
IL146144A0 IL14614400A IL14614400A IL146144A0 IL 146144 A0 IL146144 A0 IL 146144A0 IL 14614400 A IL14614400 A IL 14614400A IL 14614400 A IL14614400 A IL 14614400A IL 146144 A0 IL146144 A0 IL 146144A0
Authority
IL
Israel
Prior art keywords
safe
recombinant lentivirus
producing high
high titer
lentivirus vectors
Prior art date
Application number
IL14614400A
Other languages
English (en)
Original Assignee
Cell Genesys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Genesys Inc filed Critical Cell Genesys Inc
Publication of IL146144A0 publication Critical patent/IL146144A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
    • C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
IL14614400A 1999-04-29 2000-04-26 Method and means for producing high titer, safe, recombinant lentivirus vectors IL146144A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13167199P 1999-04-29 1999-04-29
PCT/US2000/011097 WO2000066759A1 (fr) 1999-04-29 2000-04-26 Procede et moyens de production de vecteurs lentiviraux recombinants surs et a titre eleve

Publications (1)

Publication Number Publication Date
IL146144A0 true IL146144A0 (en) 2002-07-25

Family

ID=22450511

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14614400A IL146144A0 (en) 1999-04-29 2000-04-26 Method and means for producing high titer, safe, recombinant lentivirus vectors

Country Status (9)

Country Link
US (2) US7250299B1 (fr)
EP (2) EP1171624B1 (fr)
JP (1) JP4979851B2 (fr)
AT (2) ATE528406T1 (fr)
AU (1) AU778698B2 (fr)
CA (1) CA2370103C (fr)
DE (1) DE60035676T2 (fr)
IL (1) IL146144A0 (fr)
WO (1) WO2000066759A1 (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994136A (en) * 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
EP1301214A2 (fr) * 2000-05-26 2003-04-16 Chiron Corporation Procedes de transduction de cellules neuronales cerebelleuses par le biais de vecteurs de lentivirus
US6808905B2 (en) 2001-05-14 2004-10-26 Cell Genesys, Inc. Lentiviral vectors encoding clotting factors for gene therapy
JP2006516548A (ja) 2002-12-30 2006-07-06 アンジオテック インターナショナル アクツィエン ゲゼルシャフト 迅速ゲル化ポリマー組成物からの薬物送達法
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
EP2418281B1 (fr) 2003-10-24 2016-06-01 Gencia Corporation Procédés et compositions pour l'administration de polynucléotides
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
GB0702695D0 (en) * 2007-02-12 2007-03-21 Ark Therapeutics Ltd Production of vectors
AU2008314486B2 (en) 2007-10-15 2014-06-26 Jingang Medicine (Australia) Pty Ltd Construct system and uses therefor
US9795658B2 (en) 2010-04-20 2017-10-24 Admedus Vaccines Pty Ltd Expression system for modulating an immune response
WO2012170431A2 (fr) * 2011-06-06 2012-12-13 Bluebird Bio, Inc. Systèmes perfectionnés de commutation génique
DK2790737T3 (en) 2011-12-12 2019-03-18 Childrens Hospital Philadelphia COMMERCIAL LARGE SCALE LENTIVIRUS VECTOR-MANUFACTURING SYSTEM AND VECTORS MADE THEREOF
EP2854837A4 (fr) 2012-06-05 2016-06-29 Univ Australian Vaccination avec des antagonistes de l'interleukine-4
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
US20150368360A1 (en) 2013-02-06 2015-12-24 Anthrogenesis Corporation Modified t lymphocytes having improved specificity
EP4223772A3 (fr) 2013-02-15 2023-10-18 Bioverativ Therapeutics Inc. Gene optimise du facteur viii
US10238690B2 (en) 2013-03-15 2019-03-26 Celgene Corporation Modified T lymphocytes comprising an inducible caspase and methods of apoptosis
US9925248B2 (en) 2013-08-29 2018-03-27 Temple University Of The Commonwealth System Of Higher Education Methods and compositions for RNA-guided treatment of HIV infection
US10982189B2 (en) 2014-07-11 2021-04-20 Celgene Corporation Methods of improving vector transduction efficiency into T lymphocytes
SG11201701111SA (en) 2014-08-12 2017-03-30 Anthrogenesis Corp Car-t lymphocytes engineered to home to lymph node b cell zone, skin, or gastrointestinal tract
JP7110108B2 (ja) 2015-12-09 2022-08-01 ジンガン メディスン（オーストラリア） プロプライアタリー リミティド 治療用免疫調節組成物
SG10201913278PA (en) 2016-02-01 2020-02-27 Bioverativ Therapeutics Inc Optimized factor viii genes
EP3443001A4 (fr) 2016-04-11 2020-04-29 Obsidian Therapeutics, Inc. Systèmes de biocircuits régulés
WO2018018082A1 (fr) 2016-07-26 2018-02-01 The Australian National University Compositions immunostimulantes et utilisations de celles-ci
WO2018075820A2 (fr) 2016-10-20 2018-04-26 Celgene Corporation Récepteurs antigéniques chimériques hétérodimérisables à base de céréblon
GB201706394D0 (en) 2017-04-21 2017-06-07 Ospedale San Raffaele Srl Gene Therapy
TW201946929A (zh) 2018-02-01 2019-12-16 美商生物化學醫療公司 表現因子ｖｉｉｉ之慢病毒載體之使用
AU2020361533A1 (en) 2019-10-08 2022-04-28 Trustees Of Boston College Proteins containing multiple, different unnatural amino acids and methods of making and using such proteins
WO2022074464A2 (fr) 2020-03-05 2022-04-14 Neotx Therapeutics Ltd. Méthodes et compositions pour le traitement du cancer à l'aide de cellules immunitaires
AU2021202658A1 (en) 2021-04-28 2022-11-17 Fondazione Telethon Gene therapy
CN115247190B (zh) * 2021-04-28 2024-06-18 沛尔生技医药股份有限公司 慢病毒包装系统、其所制得的慢病毒及经该慢病毒转导的细胞及其应用
TWI758171B (zh) 2021-04-28 2022-03-11 沛爾生技醫藥股份有限公司 慢病毒包裝系統及使用其以提高宿主細胞之慢病毒產量的方法
WO2023015283A1 (fr) 2021-08-06 2023-02-09 Celgene Corporation Compositions et procédés de dégradation sélective de protéines modifiées
KR20240057457A (ko) 2021-08-16 2024-05-02 헤모제닉스 파마슈티컬스 엘엘씨 항-flt3 항체, car, car t 세포 및 사용 방법
GB202206346D0 (en) 2022-04-29 2022-06-15 Ospedale San Raffaele Srl Gene therapy

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716826A (en) 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
FR2629469B1 (fr) 1988-03-31 1990-12-21 Pasteur Institut Retrovirus recombinant defectif, son application a l'integration de sequences codantes pour des proteines determinees dans le genome de cultures cellulaires infectables par le retrovirus sauvage correspondant et adns recombinants pour la production de ce retrovirus recombinant
US5614404A (en) 1988-06-10 1997-03-25 Theriod Biologics, Incorporated Self-assembled, defective, non-self-propagating lentivirus particles
US5665577A (en) 1989-02-06 1997-09-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
WO1991000047A1 (fr) 1989-06-30 1991-01-10 The Regents Of The University Of California Detection de retrovirus
WO1993017118A2 (fr) 1992-02-28 1993-09-02 Syngenix Limited Vecteurs non oncoviraux a encapsidation defectueuse bases sur le virus simiesque de mason-pfizer et le vih
US5834256A (en) 1993-06-11 1998-11-10 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
US6051427A (en) 1993-06-11 2000-04-18 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
US5589362A (en) * 1993-06-14 1996-12-31 Basf Aktiengesellschaft Tetracycline regulated transcriptional modulators with altered DNA binding specificities
US5591579A (en) 1993-12-21 1997-01-07 Washington University Indicator cell line for detecting RNA viruses and method therefor
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
AU2419595A (en) * 1994-05-10 1995-11-29 Hisamitsu Pharmaceutical Co., Inc. Recombinant human immunodeficiency virus vector and process for producing the same
WO1995032300A1 (fr) 1994-05-23 1995-11-30 University Of Medicine & Dentistry Of New Jersey Destruction biologique selective des cellules tumorales
US5693508A (en) 1994-11-08 1997-12-02 Chang; Lung-Ji Retroviral expression vectors containing MoMLV/CMV-IE/HIV-TAR chimeric long terminal repeats
US5681746A (en) 1994-12-30 1997-10-28 Chiron Viagene, Inc. Retroviral delivery of full length factor VIII
US5650309A (en) 1995-05-16 1997-07-22 The Regents Of The University Of California Viral vectors
US6013516A (en) * 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
EP0863988A1 (fr) 1995-11-28 1998-09-16 Clinical Technologies, Inc. Vih recombine, cellules d'encapsidation modifiees et methode de traitement du syndrome d'immunodeficience acquise
US5750383A (en) 1996-05-14 1998-05-12 Boyce Thompson Institute For Plant Research, Inc. Baculovirus cloning system
EP0970201A1 (fr) * 1996-09-17 2000-01-12 The Salk Institute For Biological Studies Vecteurs retroviraux pouvant transduire des cellules ne se divisant pas
PT904392E (pt) 1996-10-17 2001-06-29 Oxford Biomedica Ltd Vectores retrovirais
GB9621680D0 (en) * 1996-10-17 1996-12-11 Oxford Biomedica Ltd Lentiviral vectors
US6207455B1 (en) 1997-05-01 2001-03-27 Lung-Ji Chang Lentiviral vectors
AU8576298A (en) 1997-07-18 1999-02-10 Chiron Corporation Lentiviral vectors
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
WO1999036511A2 (fr) * 1998-01-16 1999-07-22 Chiron Corporation Vecteurs de therapie genique du virus de l'immunodeficience feline
DE69936577T2 (de) * 1998-05-13 2008-04-30 Genetix Pharmaceuticals Inc., Cambridge Lentivirale Verpackungszellen

Also Published As

Publication number Publication date
JP4979851B2 (ja) 2012-07-18
US8652837B2 (en) 2014-02-18
AU778698B2 (en) 2004-12-16
EP1171624A1 (fr) 2002-01-16
EP1849873B1 (fr) 2011-10-12
EP1171624A4 (fr) 2002-06-26
CA2370103C (fr) 2011-08-02
US20080241929A1 (en) 2008-10-02
EP1171624B1 (fr) 2007-07-25
CA2370103A1 (fr) 2000-11-09
WO2000066759A1 (fr) 2000-11-09
AU4489700A (en) 2000-11-17
US7250299B1 (en) 2007-07-31
ATE368122T1 (de) 2007-08-15
EP1849873A1 (fr) 2007-10-31
ATE528406T1 (de) 2011-10-15
DE60035676D1 (de) 2007-09-06
JP2003508017A (ja) 2003-03-04
DE60035676T2 (de) 2008-04-30

Similar Documents

Publication Publication Date Title
IL146144A0 (en) Method and means for producing high titer, safe, recombinant lentivirus vectors
EP1036182A4 (fr) Procedes et moyens de production de vecteurs de lentivirus de recombinaison surs et a titre eleve
GB2369121A (en) Producer cell for the production of retroviral vectors
GB9803351D0 (en) Anti-viral vectors
EP0675198A4 (fr) Gene identifiant un cytoplasme vegetal sterile et procede pour preparer un vegetal hybride a l'aide de celui-ci.
EP0629608A3 (fr) Dérivés de l'acide N-Acylé-N,N',N'-éthylène-diaminetriacétique et procédé pour leur préparation.
AU7565387A (en) Bimodal star-block copolymers, showing excellent optical properties and resilience, and process for their manufacture
IL181695A0 (en) Methods for cultivating cells and propagating viruses
DE68907447D1 (de) Geblasene, einstueckige flasche und verfahren zur herstellung derselben.
AU2419595A (en) Recombinant human immunodeficiency virus vector and process for producing the same
GR851617B (fr)
EP0619280A3 (fr) Polymetalosilazane, procédé de sa fabrication, céramique à base de nitrure de silicium et procédé de sa fabrication.
NZ239948A (en) Hiv gp160 modified at positions 502 and 510, vaccines and recombinant methods for producing modified gp160
BR8905861A (pt) Processo para a separacao de dioxido de carbono gasoso,processo para preparacao de oxido de etileno e produtos obtidos
HUT59136A (en) Process for producing 3-(pyroglutamyl)-l-thiazolidine-4-carboxylic acid and its derivatives
AU8172394A (en) Thermal treated coal, and process and apparatus for preparing the same
EP0668254A3 (fr) Procédé de fabrication de corps en carbure de silicium résistant à la température élevée ayant aucune ou une petite teneur d'oxygène.
EP0440207A3 (en) Expression of hiv1 and hiv2 polypeptides and use thereof
ZA927861B (en) Artificial standard and control sera, processes for the preparation thereof and the use thereof.
EP0974694A4 (fr) Fibre formant un chelate, procede de preparation associe et utilisation de cette fibre
AU7073194A (en) Process for eliminating migrated elements from reusable plastic containers for foodstuffs
EP0636611A3 (en) Optically active 1,4-dihydropyridine derivatives and process for preparing the same.
HU9402646D0 (en) Anomere fluoro-ribosyl-amines
WO1990012807A3 (fr) Procede et anticorps purifies a specificite elevee contre des produits genetiques, y compris des retinoblastomes
AU8445891A (en) Scavenging port for passing gases and/or solids into a metallurgical melt, and a process for manufacturing the port

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
EXP Patent expired